---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092253"
form_type: "8-K"
ticker: "ZBH"
cik: "0001136869"
company_name: "ZIMMER BIOMET HOLDINGS, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:37:00.332529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zimmer Biomet Q2 adjusted EPS $2.01 beats; revenue +5.6% CC; full-year guidance reaffirmed

## Summary
- Q2 net sales $1.942B (+5.6% constant currency); diluted EPS $1.18 GAAP, $2.01 adjusted, exceeding expectations.
- Net earnings $242.8M GAAP; adjusted net earnings $415.0M.
- FY 2024 reported revenue guidance lowered to 4.0%-5.0% on FX; CC revenue growth 5.0%-6.0% and adjusted EPS $8.00-$8.15 reaffirmed.
- Signed definitive agreement to acquire OrthoGrid Systems (AI hip guidance); also entered THINK Surgical and CBRE partnerships.

## SEC filing metadata
- accession: 0000950170-24-092253
- form_type: 8-K
- ticker: ZBH
- cik: 0001136869
- company_name: ZIMMER BIOMET HOLDINGS, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1136869/000095017024092253/0000950170-24-092253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1136869/000095017024092253/zbh-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092253
- JSON: https://secwatch.observer/filing/0000950170-24-092253.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.